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ARTICLE
Association of PET-based estradiol-challenge test
for breast cancer progesterone receptors with
response to endocrine therapy
Farrokh Dehdashti1,2✉, Ningying Wu 1,3, Cynthia X. Ma 1,4, Michael J. Naughton5,
John A. Katzenellenbogen 6 & Barry A. Siegel 1,2
Estrogen receptor (ER) testing of breast cancer imperfectly predicts response to endocrine
therapy (ET). We hypothesize that a brief estradiol challenge will increase tumor proges-
terone receptor (PgR) levels only in tumors with functional ER. In this prospective, phase 2,
single-center, single-arm trial (NCT02455453), we report the association of response to ET
with change in tumor uptake of the progestin analog, 21-[18F]fluorofuranylnorprogesterone
(FFNP), before and after a one-day estradiol challenge. In 43 postmenopausal women with
advanced ER+ breast cancer, we show a post-challenge increase in tumor FFNP uptake only
in 28 subjects with clinical benefit from ET (responders), but not in 15 without clinical benefit
(nonresponders) (p < 0.0001), indicating 100% sensitivity and specificity. We further show
significantly longer survival (p < 0.0001) in the responding subjects. Our results demonstrate
that change in tumor FFNP uptake after estradiol challenge is highly predictive of response to
ET in women with ER+ breast cancer.
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Over 70% of patients with breast cancer have hormone-receptor-positive disease, characterized as being estrogen-receptor-positive (ER+), progesterone-receptor-positive
(PgR+), or both1,2. ER positivity has significant prognostic value
and is a main predictor of sensitivity to endocrine therapy (ET).
However, up to 50% of ER+ breast cancers do not respond to
ET3. There is an unmet clinical need to develop more precise
predictive biomarkers.
PgR transcription is directly regulated by estrogen action
through the ER, and the measurement of PgR levels was originally
proposed as a way to identify ER+ tumors with functional ER
capable of mediating ET response4. However, assessment of PgR
by immunohistochemistry (IHC) has been limited by several
factors, including variable standards for positivity and lack of
reproducibility due to sampling errors5. More significantly, PgR
levels are elevated only when ER is functional and estrogen is
present; menopausal estrogen levels are likely insufficient to
maximally elevate PgR levels6, although local levels of estradiol in
the tumors themselves might be higher than circulating levels due
to intratumoral estrogen biosynthesis7. These limitations con-
tribute to inconsistent data observed in clinical studies assessing
the value of PgR for predicting ET benefit. Clearly, better methods
are needed to determine the quantity and functional status of
tumor ER, as well as PgR, in order to reliably identify patients
most likely to benefit from ET.
We developed a PgR-binding, progestin-analog radio-
pharmaceutical (21-[18F]fluorofuranylnorprogesterone [FFNP])8,
and demonstrated significantly greater FFNP uptake in PgR+
than PgR– breast cancers by positron emission tomography
(PET)9. Additionally, in mouse mammary tumors, we found that
the increase in FFNP uptake after estrogen treatment was both
rapid and robust10; similar observations were made by others in
human breast cancer xenograft models11,12. We undertook this
study to determine functional ER in patients with ER+ breast
cancer by using FFNP-PET to measure the change in tumor PgR
levels in vivo in response to a brief dosage of estradiol. In this
work, we show that this PgR-based estradiol-challenge test, as an
in vivo assessment of tumor ER functional status, would be a
much stronger predictor of benefit from ET than the mere pre-
sence of ER and/or PgR by IHC in a biopsy sample of a single
lesion.
Results
Patient demographics. Forty-seven women with ER+, human
epidermal growth factor receptor 2-negative (HER2−) locally
advanced, and locally recurrent or metastatic breast cancer were
enrolled between June 2015 and December 2018 (see STARD flow
diagram in Supplementary Fig. 1). Four subjects were excluded
from the response analysis set: 1 declined ET, two had only
hepatic metastatic disease (precluding assessment of tumor
uptake because of intense FFNP uptake in normal liver), and 1
had tumor deposits with no definite uptake on either FDG ([18F]
fluorodeoxyglucose)-PET/CT or FFNP-PET/CT. In the remain-
ing 43 subjects, the median age was 60 years (range 46–82 years);
37 subjects (86%) had metastatic disease and six (14%) had either
locally advanced primary cancers (n= 5) or locally recurrent
disease (n= 1) (Table 1). Receptor status was determined for the
original locally advanced primary tumor or a histologically pro-
ven recurrent or metastatic lesion in 21 subjects; in the remaining
Table 1 Patient characteristics by clinical benefit.
Characteristics All Nonresponders Responders pa
No. of patients, n (%) 43 (100%) 15 (65%) 28 (35%)
Response at 6 months, n (%)
Objective response 15 (35%) 0 (0%) 15 (54%)
Stable disease 13 (30%) 0 (0%) 13 (46%)
Progressive disease within 6 months 15 (35%) 15 (100%) 0 (0%)
Age (years), median (Q1–Q3)b 60 (54–66) 61 (55–66) 58 (54–66) 0.6367
Race, n (%) 0.4508
Caucasian 33 (77%) 13 (87%) 20 (71%)
African American 10 (23%) 2 (13%) 8 (29%)
Disease status, n (%) 0.6427
Metastatic disease/chest wall recurrence 38 (88%) 14 (93%) 24 (86%)
Locally advanced 5 (12%) 1 (7%) 4 (14%)
PgR status, n (%) 0.7817
Negative 16 (37%) 6 (40%) 10 (36%)
Positive 27 (63%) 9 (60%) 18 (64%)
Heterogeneous tumor FFNP increase with estradiol challenge, n (%) 1.0000
No 33 (77%) 12 (80%) 21 (75%)
Yes 10 (23%) 3 (20%) 7 (25%)
Disease site, n (%) 0.1001
Bone 9 (21%) 4 (27%) 5 (18%)
Soft tissue 11 (26%) 2 (13%) 9 (32%)
Visceral 2 (5%) 2 (13%) 0 (0%)
Bone & soft tissue 7 (16%) 1 (7%) 6 (21%)
Bone & visceral 4 (9%) 2 (13%) 2 (7%)
Soft tissue & visceral 6 (14%) 1 (7%) 5 (18%)
Bone, soft tissue, & visceral 4 (9%) 3 (20%) 1 (4%)
Disease site, n (%) 0.1094
Bone and/or soft tissue 27 (63%) 7 (47%) 20 (71%)
Visceral and/or bone, soft tissue 16 (37%) 8 (53%) 8 (29%)
Prior neoadjuvant therapy, n (%) 0.4581
None 34 (79%) 13 (87%) 21 (75%)
1 Regimen 9 (21%) 2 (13%) 7 (25%)
Prior adjuvant therapy, n (%) 0.2275
None 16 (37%) 3 (20%) 13 (46%)
1 Regimen 12 (28%) 5 (33%) 7 (25%)
2+ Regimens 15 (35%) 7 (47%) 8 (29%)
Prior metastatic therapy, n (%) 0.0078
None 25 (58%) 4 (27%) 21 (75%)
1–2 Regimens 8 (19%) 5 (33%) 3 (11%)
3+ Regimens 10 (23%) 6 (40%) 4 (14%)
aFisher’s exact test (if cell count is less than 5) or Chi-square test for categorical variable; Kruskal-Wallis test for continuous variable.
bQ1 is 25th percentile, and Q3 is 75th percentile. The range of age is 46–82 years.
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22 subjects, receptor status of metastatic or recurrent disease was
assumed to be the same as that of the original primary tumor.
All tumors were ER+ and 27 were PgR+. Among the 43 subjects,
11 had soft tissue disease, 7 had soft tissue and bone disease,
6 had soft tissue and visceral disease, 2 had visceral-only disease,
9 had bone-only disease, 4 had bone and visceral disease, and 4
had soft tissue, bone and visceral disease. The imaging data were
derived from 134 different sites of disease involving bone (n=
70), pleura (n= 2), omentum (n= 3), lymph nodes (n= 32), lung
(n= 9), or breast and chest wall (n= 18).
Twelve subjects (28%) were treatment-naïve, but the majority
had received various forms of prior systemic therapy, with most
being ET-based regimens (Tables 1 and 2); 9 patients had
neoadjuvant therapy, 27 had adjuvant therapy, and 18 had
therapy in the metastatic setting. Following completion of PET
studies, the subjects underwent various types of ET (Table 2).
Adverse events. There were no definite adverse or clinically
detectable pharmacological effects associated with FFNP admin-
istration, and no significant changes in vital signs were observed.
However, with estradiol administration, 11 subjects reported
transient grade 1 (diarrhea 3, nausea 3, vomiting 1, oral dys-
esthesia 1, fatigue 2, musculoskeletal pain 3, headache 2, par-
esthesia 1) and grade 2 (vomiting 1, cramping 1, back pain 1)
adverse effects; these may have been related to estradiol and
subsided before or shortly after the second FFNP administration.
Response to endocrine therapies. Fifteen subjects (35%) were
nonresponders and experienced disease progression within
6 months of initiating ET (Table 1). Twenty-eight subjects (65%)
were responders and experienced clinical benefit (no disease
progression within 6 months), including 15 (54%) with partial
response and 13 (46%) with stable disease (Figs. 1 and 2).
Baseline tumor FFNP uptake did not differ significantly
between responding and nonresponding subjects (median
(Q1–Q3): 3.7 (2.6–4.7) versus 2.8 (2.3–4.4), p= 0.18) (Table 3).
Following estradiol challenge, however, tumor FFNP uptake was





Fig. 1 Responder. A woman with newly diagnosed ER+/PR+/HER2−
invasive ductal carcinoma with metastatic disease at diagnosis in left
axillary lymph nodes and a rib. She was treated with an aromatase inhibitor
and palbociclib after the estradiol challenge test and had marked
improvement of all lesions. Selected fused transaxial 21-[18F]fluorofuranyl-
norprogesterone [FFNP]-PET/CT (top) and CT (bottom) images at
baseline show intense FFNP uptake in the primary left breast cancer
(arrows). One day after estradiol, tumor FFNP uptake measured as the
maximum standardized uptake value (SUVmax) (arrows) was increased by
78% from baseline.





Fig. 2 Nonresponder. A woman with ER+/PR−/HER2− invasive ductal
carcinoma post neoadjuvant ET and breast conserving surgery, who
developed metastatic disease to left prevascular and aortopulmonary lymph
nodes. She was treated with an aromatase inhibitor after the estradiol
challenge test but developed progressive disease. Selected fused transaxial
FFNP-PET/CT (top) and CT (bottom) images at baseline show minimal
FFNP uptake in the prevascular lymph node metastasis (arrows). One day
after estradiol, tumor FFNP uptake measured as the maximum standardized
uptake value (SUVmax) (arrows) is unchanged.





ET and chemotherapy 11
ET, chemotherapy, and CDK 4/6 inhibitor 3
ET and CDK 4/6 inhibitor 4
ET, chemotherapy, and mTOR inhibitor 3
ET, CDK 4/6 inhibitor, and mTOR inhibitor 1
ET, chemotherapy, CDK 4/6 inhibitor, and AKT inhibitor 2
ET, mTOR inhibitor, and chemotherapy 1
ET, chemotherapy, mTOR inhibitor, and trastuzumab* 1
ET during study and response within 6 months
Aromatase inhibitor (2 PD, 1 SD, 6 PR) 9
Tamoxifen and AKT inhibitor (1 SD) 1
Aromatase inhibitor and CDK 4/6 inhibitor (5 PD, 8 SD, 7 PR) 20
Fulvestrant and CDK 4/6 inhibitor (5 PD, 1 SD) 6
Aromatase inhibitor and mTOR inhibitor (3 PD) 3
Aromatase inhibitor, gonadotropin-releasing hormone agonist,
and mTOR inhibitor (1 SD)
1
Aromatase inhibitor, CDK 4/6 inhibitor, and mTOR
inhibitor (1 PR)
1
Aromatase inhibitor, gonadotropin-releasing hormone
agonist (1 PR)
1
Aromatase inhibitor, CDK 4/6 inhibitor, and gonadotropin-
releasing hormone agonist (1 PR)
1
ET endocrine therapy, PD progressive disease, SD stable disease, PR partial response, AKT
protein kinase B.
*Patient had ER+/PR–/HER2+ primary breast cancer and developed ER+/PR+/HER2–
metastatic disease several years later.
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significantly increased compared to baseline in responding
subjects but not in nonresponding subjects, and it actually
decreased relative to baseline in many of the latter (p < 0.0001)
(Fig. 3 and Supplementary Table 1). The median percentage
change in tumor FFNP uptake in responding subjects was 25.4%
(Q1–Q3: 11.9–35.5%); and in nonresponding subjects it was
−0.7% (Q1–Q3:−23.4% to 0.4%). Figure 3 shows the complete
separation based on the percentage change of FFNP standardized
uptake values (SUV) in responding and nonresponding subjects.
That is, the minimum value of percentage change in SUV (i.e.,
7.4) among responders was greater than the maximum value of
percentage change in SUV (i.e., 6.7) among nonresponders. Using
any value of the percentage change in SUV between 6.7 and
7.4 (e.g., 7) as a cutoff to indicate clinical benefit results in 100%
sensitivity, specificity, positive-predictive value (PPV), and
negative-predictive value (NPV). The percentage change of
SUV did not differ significantly across different types of prior
therapy (p= 0.47) (Fig. 4).
As shown in Fig. 3, all of the 28 responders had a SUV change
≥7% and all of the 15 nonresponders had a SUV change <7%.
Accordingly, the Kaplan-Meier overall survival (OS) curve based
on clinical benefit and that based on the percentage change in the
FFNP SUV following estradiol were identical (Fig. 5a). Clinical
responders (subjects with SUV change ≥7%) had a significantly
longer survival (p < 0.0001) than clinical nonresponders (subjects
with SUV change <7%). With a median follow-up of 27.1 months,
the estimated median survival was 22.6 months in nonresponding
subjects (95% CI 7.1–37.4 months), and the median survival has
not been reached among responding subjects. The baseline tumor
FFNP uptake was not significantly associated with OS (p= 0.22)
(Fig. 5b), when dichotomized at an optimal cut-point of 4.16,
which was determined by the log-rank test statistic with an
adjustment for bias13 to result in a most significant split.
As shown in Table 1, unlike the predictive value of the change in
tumor FFNP uptake, other features were not associated with clinical
benefit, except for prior metastatic disease therapy (p= 0.0078).
Further subgroup analysis showed that the SUV change still can
significantly distinguish nonresponders and responders among
patients with prior metastatic disease therapy (n= 18, p= 0.0005)
and among those without such therapy (n= 25, p= 0.0019).
Intra-subject tumor uptake change after estradiol challenge was
homogeneous in 33 subjects (77%) and heterogeneous (defined as
any increase in uptake in one or more lesions, while one or more
other lesions had decreased or no change in uptake) in 10 (23%),
occurring in 7 (25%) responding and 3 (20%) nonresponding
subjects (p= 1.0 for association with clinical benefit) (Table 1).
The tumors were PgR+ in 18 (64%) of 28 responding and 9
(60%) of 15 nonresponding subjects (p= 0.78). There was no
Table 3 Summary of FFNP-PET findings.








FFNP uptake prior to estradiol challenge
Pretreatment SUVc 3.7 (2.6–4.7) 2.8 (2.3–4.4) 0.18
FFNP uptake after estradiol challenge
Percentage
change in SUV
25.4 (11.9–35.5) −0.7 (−23.4 to 0.4) <0.0001
aQ1= 25th percentile, Q3= 75th percentile.
bKruskal-Wallis test.
cSUV= standardized uptake value.


















































Fig. 3 Tumor FFNP uptake in responders and nonresponders. a Baseline SUV, b Percent change in SUV after estradiol challenge.
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significant association between clinical benefit and serum
estradiol level at baseline and after estradiol challenge (p= 0.37
and p= 0.25, respectively) (Table 4a). In addition, there was no
significant association between change in tumor FFNP uptake
and serum estradiol level at baseline and after estradiol challenge
(p= 0.14 and p= 0.17, respectively) (Table 4b).
Discussion
We found that an estradiol-challenge test that monitors an
increase in tumor PgR by FFNP-PET can rapidly and accurately
predict response or lack thereof to subsequent ET in patients with
advanced ER+ breast cancer. Most of our subjects (72%) had
received prior systemic therapy (Table 2). The type of previous
therapy did not affect changes in FFNP uptake after estradiol
challenge (Fig. 4), and a heterogeneous response to estradiol had
no significant association with clinical benefit (p= 1.0). In addi-
tion, there was not a significant correlation between serum
estradiol level, at baseline or after estradiol challenge, and the
change in tumor FFNP after estradiol challenge or clinical benefit
(Table 4). All subjects with a > 6.7% increase in FFNP uptake after
estradiol challenge, classified as having functional ER, were sub-
sequently identified as responders (100% PPV and NPV). They
also had a significantly longer OS than did those with a decrease
in FFNP or an increase ≤6.7%, identical to that of subjects who
were subsequently identified as nonresponders (Fig. 5a).
Of note, most of our subjects (28 of 43) received CDK4/6
inhibitor/ET combination therapy, and the test identified all 10
nonresponders (Table 2). This suggests that functional ER could
also be important for the efficacy of CDK4/6 inhibitors in ER+
breast cancer. This is consistent with the preclinical observation
that CDK4/6 inhibitors are preferentially effective in luminal
breast cancer14. Further evaluation of the estradiol-challenge test
with FFNP-PET in predicting CDK4/6 inhibitor efficacy in ER+
breast cancer is warranted.
Our original hormone-challenge test was developed when
tamoxifen was the preferred ET agent, and it became known that
some patients who ultimately responded to tamoxifen experi-
























No Therapy Prior Endocrine  
Therapy 
Prior Endocrine 
Therapy + Other Types  
of Therapy 
Percent Change in SUV by Therapy 
Fig. 4 Percent change in tumor FFNP uptake with estradiol challenge based on prior therapies. Relationship of percent change in standardized uptake
value (SUV) for FFNP after estradiol challenge to previous subject therapy.
Table 4 . Relationship of serum estrogen level and response
(a) and change in FFNP uptake after estradiol challenge (b).
(a) Relationship between serum estrogen level and clinical response
(n= 37)








Prior to estradiol challenge
Baseline estradiol level 15.1 (13.4–19.1) 13.3 (8.6–19.3) 0.37
After estradiol challenge
Change of estradiol against
baselinec
9.9 (5.8–15.5) 13.2 (10.2–21.8) 0.25






Prior to estradiol-challenge test
Baseline estradiol level 0.25 0.14
After estradiol-challenge test
Change rate of estradiol levelc −0.23 0.17
aQ1= 25th percentile, Q3= 75th percentile.
bKruskal-Wallis test.
cCalculated as (estradiol level after estradiol challenge− baseline estradiol level)/baseline
estradiol level.
dSpearman-Brown test.
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initiating tamoxifen therapy. This tamoxifen clinical flare was
ascribed to an initial partial agonist activity of tamoxifen15, but
was not a reliable predictor of ET response16. By monitoring
tumor metabolism with FDG-PET, at baseline and after
7–10 days of tamoxifen, we could detect a tamoxifen metabolic
flare (increase in tumor SUV on the post-tamoxifen FDG-PET)
that was highly predictive of benefit from continued tamoxifen
therapy in largely treatment-naïve patients (PPV= 91%; NPV=
94%). These values were marginally greater than those based on
16α-[18F]fluoroestradiol (FES)-PET for detecting ER at base-
line17. When aromatase inhibitors replaced tamoxifen as ET,
we replaced the 7–10 days tamoxifen challenge with the current
one-day estradiol challenge, which was followed by treatment
with aromatase inhibitors or fulvestrant18. In more heavily pre-
treated subjects, we also found high predictive values for ET
benefit from a post-estradiol increase in tumor FDG uptake (PPV
= 100%; NPV= 94%), with greater predictive accuracy in this
subject cohort than baseline FES-PET (PPV= 50%; NPV= 81%).
Despite good predictive values, the percentage change in FDG
uptake and separation between ET responders and non-
responders in these FDG-PET-based hormone-challenge studies



















Overall Survival by Percent Change in SUVa
b
0 6 36 42 4818 24 3012
≥ 7% 28 27 10 9 022 19 1525
























Overall Survival by Pretreatment SUV
0 6 36 42 4818 24 3012
≥ 4.16 13 10 3 1 07 6 49







Fig. 5 Overall survival results. a Dichotomized based on percent change in standardized uptake value (SUV) for FFNP after estradiol challenge (≥7% vs.
<7%). The overall survival results based on clinical response (responders versus nonresponders) were identical to those based on percent change in FFNP
SUV. b Dichotomized based on the optimal cut-off value of the baseline FFNP SUV (≥4.16 vs. <4.16).
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to fast to control blood glucose and insulin levels. By contrast, the
estradiol-challenge test using FFNP-PET to measure changes in
PgR levels gave markedly greater changes in tracer uptake, with
complete separation between ET responders and nonresponders
in a more diverse cohort of patients. Also, by using PgR as a
biomarker, there is no need to monitor and control blood glucose
levels.
Prior to this clinical study, we evaluated changes in PgR levels
monitored by FFNP-PET in an ER+, hormone-responsive mouse
mammary cancer model10,19. We found large increases in FFNP
uptake after administration of estradiol and large decreases in
FFNP uptake after oophorectomy or administration of fulvestrant
in ovary-intact mice. Thus, in this mouse model, changes in
FFNP uptake accurately predicted sensitivity to estrogen addition
or ablation therapy. Accordingly, in principle, it also should be
possible clinically to test the hormone sensitivity of breast cancer
with FFNP-PET in order to monitor a decrease in PgR levels after
a period of estrogen deprivation or ER blockade. Most breast
cancer patients, however, are elderly, so their basal PgR levels
should be low, reflecting low menopausal estrogen levels. Thus,
the dynamic range for a downward change in PgR level from
estrogen deprivation or blockade in elderly patients is likely to be
less than that for the upward change we have monitored with the
estradiol-challenge test. A test for downward change in PgR levels
to predict ET responsiveness would be more feasible in pre-
menopausal breast cancer patients. It is of note that, 2 weeks after
initiating AI therapy, a decrease in the SUV for FDG was detected
in some breast cancers and correlated with low levels of the
proliferation marker Ki-67 at the time of the second image; the
relation to therapy response, however, was not reported20.
While currently, selection of ET for women with advanced
ER+ breast cancer is based on IHC assays of ER, PgR, and HER2,
there are many emerging methods based on more extensive
genomic, transcriptomic, proteomic, metabolomic, and other
information-rich characterizations of biopsy samples21–23. These
“-omic” analyses, as well as those based on specific candidate
genes of interest on tumor tissue biopsies largely remain inves-
tigational. Assessment of Ki-67 by IHC following initiation of
neoadjuvant ET may be a promising biomarker of endocrine
sensitivity, but requires at least 2 weeks of treatment24. In addi-
tion, standardization of the Ki-67 analysis is required before its
eventual clinical application for this purpose25. Some of these
approaches may prove to have good predictive value for benefit
from ET alone. It will take some time, however, to determine the
accuracy of such tests, and they will be affected by the afore-
mentioned concerns regarding sampling error and within-subject
tumoral heterogeneity associated with needle biopsy, as well as
intra-subject heterogeneity and biopsy-inaccessible lesions.
Our study has several limitations. It is a single-institution study
with a relatively small sample size and with all imaging performed
on a single PET/CT scanner. Despite the excellent separation of
responders from nonresponders, assessment of the test–retest
repeatability of measurements of FFNP uptake should be per-
formed in future studies. Additionally, we designed this study to
have post-estradiol PET/CT performed about 24 h after the last
dosage of estradiol, but further study to find the optimal timing
will be necessary.
FFNP-PET before and after administration of estradiol over 24
h can be accomplished in as little as 2 days before ET is started
and discriminates likely responders from nonresponders with
high accuracy, thus allowing for risk stratification equivalent to
that obtained by much longer clinical observations alone. While
the results of this study are extremely promising, our findings
need to be confirmed in a multicenter trial before this method can
be used to guide ET in clinical practice.
Methods
Study design and participants. This was a prospective, single-center, single-arm
trial (NCT02455453). Postmenopausal women with ER+, HER2–, and locally
advanced, locally recurrent or metastatic breast cancer were eligible for partici-
pation if they had measurable or evaluable disease by Response Evaluation Criteria
in Solid Tumors (RECIST 1.1), had ECOG performance status 0–2, and were to be
treated with ET. ER positivity was confirmed by IHC on the primary breast cancer
or on a recurrent or metastatic lesion in all subjects. HER2 was considered negative
if scored 0 or +1 by IHC or if the HER2/CEP17 ratio was <2.0 by FISH. The study
was performed under physician-sponsored IND 76,214 and was approved by the
Institutional Review Board and the Radioactive Drug Research Committee of
Washington University School of Medicine, as well as by the Protocol Review and
Monitoring Committee of the Alvin J. Siteman Cancer Center. All subjects gave
written informed consent for study participation. The study was conducted in
accordance with the Declaration of Helsinki and the International Council on
Harmonization Guidelines for Good Clinical Practice.
All subjects underwent standard clinical evaluation, including complete history
and physical examination, complete blood count, liver function studies, and
necessary radiological examinations, e.g., CT of the chest, abdomen and pelvis,
skeletal scintigraphy, and FDG-PET/CT, as medically indicated. After initiation of
ET, the treating medical oncologist, who was blinded to the results of FFNP-PET,
evaluated subjects every 3 months (or earlier, if necessitated by symptoms or other
evidence of progression) until disease progression. The protocol did not mandate
specific timing of follow-up assessments, but it is routine clinical practice at our
institution to have imaging every 3–6 months during therapy. Clinical benefit
(defined below) was determined 6 months after beginning ET.
PET imaging and estradiol-challenge test. FFNP was prepared using an adap-
tation of a published procedure8. All subjects underwent two FFNP-PET/CT stu-
dies on 2 separate days, with imaging generally extending from the skull base to the
upper thighs (other body parts were included, as applicable based on known sites of
disease). FFNP (median dosage 9.2 mCi, range 3.9–10.6 mCi) was injected intra-
venously and imaging with a CTI/Siemens Biograph 40 HD PET/CT scanner began
approximately 40 min later. Following a CT for attenuation correction, emission
imaging was obtained (2–5 min per bed position, adjusted for subject height,
weight, and injected FFNP dosage). Scans were reconstructed at a 5-mm slice
thickness. FFNP dosage and scan parameters were matched as closely as possible
for both FFNP-PET/CT scans in each subject.
For safely evaluation, all subjects had vital signs measured within 30 min before
injection of FFNP, within 30 min after injection, and at the completion of each
imaging session. A follow-up telephone call was made to the subject 24 ± 6 h post
injection to assess for adverse events.
The estradiol challenge consisted of a total dosage of 6 mg, administered orally
as one 2-mg tablet approximately every 8 h for 3 doses within a 24-h period. The
final estradiol dose was taken at a median of 27.9 h (range 6.9–46 h) before
injection of FFNP for the second PET/CT. The 6-mg dosage is the currently
recommended daily dosage for estradiol treatment of metastatic breast cancer26,27.
Serum estradiol level was assessed with a high-sensitivity radioimmunoassay before
each of the two FFNP injections28 to document the post-challenge change in
estradiol level.
Response criteria. Response was determined in accordance with RECIST 1.1 for
patients with measurable disease29. For subjects with bone-dominant or bone-only
disease, response was evaluated by both imaging, including serial bone scintigraphy
in conjunction with assessment of FDG-PET/CT findings or other imaging studies
if performed, and clinical criteria, including tumor markers and symptoms. In
these patients, a complete response was defined as disappearance of all objective
and clinical disease, including complete normalization of radiological studies and
tumor markers. A partial response was defined as a decrease in pain with evidence
of re-calcification of known osseous lesions on radiography. Disease progression
was defined as worsening of disease on anatomical and/or functional imaging or
worsening of pain and decline in performance status. Any response that did not
meet the criteria for complete response, partial response, or progression was
defined as stable disease. For analysis of the prediction of response based on FFNP-
PET findings, response was dichotomized as follows: subjects who derived clinical
benefit, defined as achieving objective response or stable disease for at least
6 months, were considered responders and those with progressive disease within
6 months as nonresponders.
Data analysis. All FFNP-PET/CT images were evaluated semi-quantitatively by
determination of the maximum standardized uptake values (SUVmax) of tumor
foci. The percentage changes in SUVs for FFNP were recorded. In subjects with
multiple lesions, the SUVs of up to five lesions (typically, the most intense lesions)
were determined and the overall average values for all selected lesions in a given
subject were recorded and used in comparisons with clinical response. To evaluate
for intra-subject heterogeneous response to estradiol (defined as any increase in
uptake in one or more lesions, while one or more other lesions had decreased or no
change in uptake), the change in FFNP uptake after estradiol in individual lesions
was compared to baseline uptake.
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Power analysis. We assumed an ET response rate of 20–50%. Using a two-sided
independent t-test with 80% power at a 0.05 significance level, a sample of 10
responders versus 40 nonresponders (i.e., 20% response rate) could allow us to
detect a minimum of 101% SD between-group difference in terms of percentage
changes in FFNP uptake after estradiol challenge, where SD represents a pooled
standard deviation of the FFNP uptake changes among both responders and non-
responders. A sample of 25 responders versus 25 nonresponders (i.e., 50% response
rate) could allow us to detect a minimum of 80.9% SD between-group difference.
Statistical analysis. SAS version 9.4 (SAS Institute, Cary, NC) was used for all
statistical analyses. Demographic and clinical characteristics were summarized by
descriptive statistics. Associations were examined either by Kruskal-Wallis test/
Spearman-Brown test for continuous variables or Chi-square test/Fisher exact test
for categorical variables. Overall survival (OS) was defined as the duration of time
(in months) from the date of baseline PET to death from any cause. Subjects with
no death date were censored at the last follow-up date. Kaplan-Meier curves were
used to display OS difference by clinical response or dichotomized by FFNP uptake
(baseline or percentage change after estradiol challenge) and examined by the log-
rank test. The optimal cut-point of baseline FFNP uptake that gave the maximum
OS difference between the subjects with high and low SUV was determined by the
log-rank test statistic with an adjustment for bias13.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available within this article and its
supplementary files or from the authors upon reasonable request. All data and code used in
the production of this manuscript are available upon request to the corresponding author.
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